<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="800" width="600">
	<fontspec id="0" size="10" family="OBNGEH+MinionPro" color="#231f20"/>
	<fontspec id="1" size="9" family="OBNGEH+MinionPro" color="#231f20"/>
	<fontspec id="2" size="6" family="OBNGJJ+MinionMath-Capt" color="#231f20"/>
	<fontspec id="3" size="7" family="OBNGJJ+MinionMath-Capt" color="#231f20"/>
	<fontspec id="4" size="12" family="OBNGEG+Minion-Black" color="#231f20"/>
<text top="44" left="51" width="5" height="10" font="0">6</text>
<text top="44" left="373" width="176" height="10" font="0">International Journal of Alzheimer’s Disease</text>
<text top="74" left="86" width="427" height="9" font="1">Table 2: Overview of the imaging techniques dedicated to brain hemodynamics (adapted from Wintermark et al. <a href="">[27]).</a></text>
<text top="94" left="164" width="16" height="9" font="1">PET</text>
<text top="94" left="243" width="26" height="9" font="1">SPECT</text>
<text top="94" left="331" width="17" height="9" font="1">DSC</text>
<text top="94" left="416" width="15" height="9" font="1">ASL</text>
<text top="94" left="497" width="19" height="9" font="1">fMRI</text>
<text top="113" left="53" width="36" height="9" font="1">Age range</text>
<text top="108" left="135" width="74" height="9" font="1">Adults (and children</text>
<text top="118" left="143" width="59" height="9" font="1">for static exams)</text>
<text top="113" left="217" width="161" height="9" font="1">Adults (and children) Adults (and children)</text>
<text top="113" left="392" width="63" height="9" font="1">Adults + children</text>
<text top="113" left="468" width="77" height="9" font="1">Adults (and children)</text>
<text top="142" left="53" width="63" height="9" font="1">Contrast material</text>
<text top="139" left="136" width="6" height="8" font="2">15</text>
<text top="142" left="143" width="7" height="9" font="1">O</text>
<text top="145" left="149" width="3" height="8" font="2">2</text>
<text top="142" left="153" width="10" height="9" font="1">, C</text>
<text top="139" left="164" width="6" height="8" font="2">15</text>
<text top="142" left="171" width="7" height="9" font="1">O</text>
<text top="145" left="177" width="3" height="8" font="2">2</text>
<text top="142" left="181" width="11" height="9" font="1">, H</text>
<text top="145" left="192" width="3" height="8" font="2">2</text>
<text top="139" left="195" width="6" height="8" font="2">15</text>
<text top="143" left="201" width="7" height="9" font="1">O</text>
<text top="128" left="230" width="6" height="8" font="2">99</text>
<text top="132" left="236" width="45" height="9" font="1">Tc-HMPAO,</text>
<text top="139" left="226" width="6" height="8" font="2">99</text>
<text top="142" left="232" width="31" height="9" font="1">Tc-ECD,</text>
<text top="139" left="265" width="9" height="8" font="2">133</text>
<text top="142" left="274" width="12" height="9" font="1">Xe,</text>
<text top="149" left="219" width="9" height="8" font="2">123</text>
<text top="152" left="229" width="64" height="9" font="1">I-IMP (diffusible)</text>
<text top="137" left="304" width="70" height="9" font="1">Gadolinium chelate</text>
<text top="147" left="313" width="54" height="9" font="1">(nondiffusible)</text>
<text top="137" left="389" width="68" height="9" font="1">None (endogenous</text>
<text top="147" left="407" width="32" height="9" font="1">contrast)</text>
<text top="142" left="497" width="20" height="9" font="1">None</text>
<text top="167" left="53" width="58" height="9" font="1">Radiation/study</text>
<text top="167" left="154" width="36" height="9" font="1">0.5–2 mSv</text>
<text top="167" left="236" width="39" height="9" font="1">3.5–12 mSv</text>
<text top="167" left="330" width="20" height="9" font="1">None</text>
<text top="167" left="413" width="20" height="9" font="1">None</text>
<text top="167" left="497" width="20" height="9" font="1">None</text>
<text top="181" left="53" width="59" height="9" font="1">Data acquisition</text>
<text top="181" left="158" width="29" height="9" font="1">5–9 min</text>
<text top="181" left="238" width="35" height="9" font="1">10–15 min</text>
<text top="181" left="330" width="19" height="9" font="1">1 min</text>
<text top="181" left="407" width="32" height="9" font="1">5–10 min</text>
<text top="196" left="53" width="57" height="9" font="1">Data processing</text>
<text top="196" left="156" width="32" height="9" font="1">5–10 min</text>
<text top="196" left="246" width="20" height="9" font="1">5 min</text>
<text top="196" left="329" width="20" height="9" font="1">5 min</text>
<text top="196" left="413" width="20" height="9" font="1">5 min</text>
<text top="214" left="53" width="74" height="9" font="1">Assessed parameters</text>
<text top="209" left="142" width="60" height="9" font="1">CBV, CBF, rOEF,</text>
<text top="219" left="137" width="71" height="9" font="1">glucose metabolism</text>
<text top="214" left="248" width="16" height="9" font="1">CBF</text>
<text top="209" left="300" width="79" height="9" font="1">CBF, CBV, MTT, TTP,</text>
<text top="219" left="308" width="63" height="9" font="1">permeability map</text>
<text top="214" left="415" width="16" height="9" font="1">CBF</text>
<text top="214" left="484" width="47" height="9" font="1">BOLD signal</text>
<text top="238" left="53" width="78" height="9" font="1">Quantitative accuracy</text>
<text top="238" left="166" width="12" height="9" font="1">Yes</text>
<text top="233" left="226" width="24" height="9" font="1">Yes for</text>
<text top="230" left="252" width="9" height="8" font="2">133</text>
<text top="233" left="261" width="25" height="9" font="1">Xe and</text>
<text top="240" left="240" width="9" height="8" font="2">123</text>
<text top="243" left="249" width="22" height="9" font="1">I-IMP</text>
<text top="238" left="303" width="73" height="9" font="1">Not in daily practice</text>
<text top="238" left="417" width="12" height="9" font="1">Yes</text>
<text top="257" left="53" width="62" height="9" font="1">Including for low</text>
<text top="267" left="53" width="52" height="9" font="1">perfused areas</text>
<text top="262" left="166" width="12" height="9" font="1">Yes</text>
<text top="262" left="230" width="52" height="9" font="1">Not applicable</text>
<text top="262" left="314" width="52" height="9" font="1">Not applicable</text>
<text top="257" left="405" width="37" height="9" font="1">Not below</text>
<text top="267" left="394" width="59" height="9" font="1">10 mL/min/100 g</text>
<text top="262" left="501" width="12" height="9" font="1">Yes</text>
<text top="282" left="53" width="56" height="9" font="1">Reproducibility</text>
<text top="282" left="167" width="11" height="9" font="1">5%</text>
<text top="282" left="249" width="14" height="9" font="1">10%</text>
<text top="282" left="327" width="26" height="9" font="1">10–15%</text>
<text top="282" left="416" width="14" height="9" font="1">10%</text>
<text top="296" left="53" width="62" height="9" font="1">Spatial resolution</text>
<text top="296" left="157" width="30" height="9" font="1">4–6 mm</text>
<text top="296" left="248" width="16" height="9" font="1">1 cm</text>
<text top="296" left="329" width="20" height="9" font="1">2 mm</text>
<text top="296" left="413" width="20" height="9" font="1">2 mm</text>
<text top="309" left="53" width="79" height="9" font="1">Minimal time interval</text>
<text top="320" left="53" width="74" height="9" font="1">between 2 successive</text>
<text top="330" left="53" width="22" height="9" font="1">exams</text>
<text top="320" left="160" width="24" height="9" font="1">10 min</text>
<text top="320" left="244" width="24" height="9" font="1">10 min</text>
<text top="320" left="327" width="24" height="9" font="1">25 min</text>
<text top="320" left="413" width="21" height="9" font="1">0 min</text>
<text top="344" left="53" width="54" height="9" font="1">Applications in</text>
<text top="354" left="53" width="67" height="9" font="1">neurodegenerative</text>
<text top="364" left="53" width="33" height="9" font="1">disorders</text>
<text top="354" left="166" width="12" height="9" font="1">Yes</text>
<text top="354" left="250" width="12" height="9" font="1">Yes</text>
<text top="354" left="334" width="11" height="9" font="1">No</text>
<text top="354" left="417" width="12" height="9" font="1">Yes</text>
<text top="354" left="501" width="12" height="9" font="1">Yes</text>
<text top="411" left="51" width="240" height="10" font="0">the ASL techniques measure CBF, with the advantage of</text>
<text top="422" left="51" width="240" height="10" font="0">not requiring contrast injection. Many researchers are now</text>
<text top="434" left="51" width="240" height="10" font="0">migrating towards the use of ASL, since it poses less risk for</text>
<text top="445" left="51" width="223" height="10" font="0">the patients than DSC and nuclear medicine techniques.</text>
<text top="457" left="66" width="225" height="10" font="0">A variety of studies in both animal models and human</text>
<text top="469" left="51" width="240" height="10" font="0">subjects have demonstrated that regional CBF maps can be</text>
<text top="480" left="51" width="240" height="10" font="0">accurately depicted by ASL <a href="">[48–50], </a>and the results obtained</text>
<text top="491" left="51" width="240" height="10" font="0">with ASL are consistent with those obtained from PET studies</text>
<text top="503" left="51" width="240" height="10" font="0"><a href="">[51], </a>since CBF and metabolic consumption are markers of</text>
<text top="514" left="51" width="103" height="10" font="0">cerebral dysfunction <a href="">[50].</a></text>
<text top="527" left="66" width="225" height="10" font="0">In clinical studies of AD and MCI, metabolic imaging</text>
<text top="538" left="51" width="240" height="10" font="0">with FDG-PET <a href="">[52, 53</a>] and SPECT <a href="">[54, 55</a>] have highlighted</text>
<text top="549" left="51" width="240" height="10" font="0">loss of activity in temporal, parietal, and frontal association</text>
<text top="561" left="51" width="240" height="10" font="0">cortex, along with PCC and precuneus. Additionally, a study</text>
<text top="573" left="51" width="77" height="10" font="0">using a covariance</text>
<text top="569" left="132" width="7" height="9" font="3">15</text>
<text top="573" left="139" width="152" height="10" font="0">O-PET pattern <a href="">[56] </a>acquired during</text>
<text top="584" left="51" width="240" height="10" font="0">rest showed increased flow in the insula, cuneus, pulvinar,</text>
<text top="596" left="51" width="240" height="10" font="0">lingual, fusiform, superior occipital, and parahippocampal</text>
<text top="607" left="51" width="240" height="10" font="0">gyri, whereas decreased flow was found in cingulate, inferior</text>
<text top="619" left="51" width="240" height="10" font="0">parietal lobe, middle and inferior frontal, and supramarginal</text>
<text top="630" left="51" width="240" height="10" font="0">and precentral gyri. These results are in agreement with the</text>
<text top="641" left="51" width="131" height="10" font="0">findings reported in ASL studies.</text>
<text top="654" left="66" width="225" height="10" font="0">In AD, medial temporal lobe is characterized by severe</text>
<text top="665" left="51" width="240" height="10" font="0">atrophy, so the detection of metabolism changes or sub-</text>
<text top="676" left="51" width="240" height="10" font="0">tle flow disturbances are difficult to evaluate with nuclear</text>
<text top="688" left="51" width="240" height="10" font="0">medicine techniques <a href="">[57–59], </a>since PET or SPECT studies</text>
<text top="699" left="51" width="240" height="10" font="0">do not correct for atrophy. Thus, one important advantage</text>
<text top="710" left="51" width="240" height="10" font="0">of combining ASL with structural MRI is the possibility of</text>
<text top="722" left="51" width="240" height="10" font="0">quantifying perfusion changes per cc of tissue in the same</text>
<text top="733" left="51" width="240" height="10" font="0">setting, allowing structure-function correlations within a</text>
<text top="411" left="309" width="240" height="10" font="0">single modality. Additionally, PET studies are prone to under-</text>
<text top="422" left="309" width="240" height="10" font="0">estimate flow in regions with high blood flow, whereas ASL</text>
<text top="434" left="309" width="240" height="10" font="0">is less affected by water permeability due to the timescales of</text>
<text top="445" left="309" width="240" height="10" font="0">imaging and tracers decay <a href="">[60]. </a>Finally, SPECT can also suffer</text>
<text top="457" left="309" width="240" height="10" font="0">from saturation effects in the uptake of the tracer <a href="">[61], </a>and it</text>
<text top="468" left="309" width="109" height="10" font="0">has a low spatial resolution.</text>
<text top="494" left="309" width="237" height="11" font="4"><b>6. What Can ASL Add to the Diagnosis Flow of</b></text>
<text top="507" left="321" width="217" height="11" font="4"><b>Patients with AD in the Amyloid-PET Era?</b></text>
<text top="529" left="309" width="240" height="10" font="0">CSF studies and amyloid-PET imaging are considered molec-</text>
<text top="540" left="309" width="240" height="10" font="0">ular biomarkers of the disease, demonstrating the presence</text>
<text top="551" left="309" width="240" height="10" font="0">of the pathogenic protein “in vivo.” Its detection, in one</text>
<text top="563" left="309" width="240" height="10" font="0">way or another, is becoming increasingly important for</text>
<text top="574" left="309" width="240" height="10" font="0">establishing the diagnosis of probable AD <a href="">[62</a>]. However,</text>
<text top="585" left="309" width="240" height="10" font="0">recent evidence shows “positive” amyloid-PET studies in</text>
<text top="597" left="309" width="240" height="10" font="0">cognitively healthy individuals; thus these findings should</text>
<text top="608" left="309" width="240" height="10" font="0">be interpreted with caution <a href="">[63</a>]. Furthermore, it involves</text>
<text top="620" left="309" width="240" height="10" font="0">significant costs beyond the reach of most centers. On</text>
<text top="631" left="309" width="240" height="10" font="0">the other hand, ASL should be considered as functional</text>
<text top="642" left="309" width="240" height="10" font="0">or indirect biomarker, such as FDG-PET, showing focal</text>
<text top="654" left="309" width="240" height="10" font="0">abnormalities in perfusion within specific brain areas due</text>
<text top="665" left="309" width="240" height="10" font="0">to an underlying neurodegenerative process disrupting the</text>
<text top="676" left="309" width="240" height="10" font="0">neurovascular coupling <a href="">[24</a>]. Thus, amyloid-PET and ASL</text>
<text top="688" left="309" width="240" height="10" font="0">provide different but complementary information, which</text>
<text top="699" left="309" width="240" height="10" font="0">ideally might be integrated together in the diagnosis process</text>
<text top="711" left="309" width="240" height="10" font="0">of patients with cognitive decline. However, amyloid-PET</text>
<text top="722" left="309" width="240" height="10" font="0">requires great economic investment, which cannot often be</text>
<text top="733" left="309" width="46" height="10" font="0">carried out.</text>
</page>
</pdf2xml>
